Organization (Other)
Meshalkin Research Institute of Pathology of Circulation
ClinicalTrials.gov lists Meshalkin Research Institute of Pathology of Circulation as lead sponsor of 118 trials. It has 2 active development programs and 16 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 1 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Meshalkin Research Institute of Pathology of Circulation: 118 lead-sponsored trials and 0 legal-entity registrations.
Disease areas (55)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Atrial Fibrillation | 29 |
| Coronary Disease | 15 |
| Coronary Artery Disease | 14 |
| Hypertension | 8 |
| Aortic Valve Stenosis | 6 |
Showing 5 of 55 disease areas.
Trials by start year as sponsor or collaborator (20)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2025 | 2 |
| 2024 | 1 |
| 2023 | 4 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 8 |
| 2019 | 5 |
| 2018 | 5 |
| 2017 | 7 |
Showing 10 of 20 years.
Prediction, not a registry value: median of 36 months from start to primary completion across 7 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 62 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (2)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Sodium warfarin | Atrial Fibrillation | Phase 3 | 2 |
| Apixaban | Atrial Fibrillation | Phase 3 | 1 |
Approved assets (16)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Sodium warfarin | 5 |
| PROPOFOL | 2 |
| SEVOFLURANE | 1 |
| 0,9% Chloride Sodium | 1 |
| Volatile Agent | 1 |
Showing 5 of 16 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 75% hit target (n=16) | 40% on time (n=15) |
Journals published in (54)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The Annals of thoracic surgery | 9 |
| Anesthesiology | 5 |
| Journal of cardiothoracic and vascular anesthesia | 5 |
| The Journal of thoracic and cardiovascular surgery | 4 |
| Circulation. Arrhythmia and electrophysiology | 3 |
Showing 5 of 54 journals.
Latest dated events (119)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-11-14 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-03-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-07-18 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 119 events.
Biomarker capability evidence (42)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| BCAR1 | Trial sponsor | Named in trial inclusion criteria |
| BCAR1 | Trial sponsor | Named in trial inclusion criteria |
| CLU | Trial sponsor | Named in trial inclusion criteria |
| CSE1L | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 42 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, organization relationships, clia clinical laboratory certificates, and biomarkers this organization publishes on.